Page last updated: 2024-08-18

allylamine and Obesity

allylamine has been researched along with Obesity in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Holst, JJ; Salen, G; Saumoy, M; Shang, Q; Xu, G	1
Bailey, CJ; Barnett, AH; Del Prato, S; Tahrani, AA	1

Reviews

1 review(s) available for allylamine and Obesity

Article	Year
Management of type 2 diabetes: new and future developments in treatment. Lancet (London, England), 2011, Jul-09, Volume: 378, Issue:9786 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Allylamine; Anticholesteremic Agents; Bariatric Surgery; Bile Acids and Salts; Cardiovascular System; Colesevelam Hydrochloride; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucokinase; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liver; Obesity; Peptides; Randomized Controlled Trials as Topic; Receptors, Dopamine D2; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Venoms	2011

Article

Year

Management of type 2 diabetes: new and future developments in treatment.

Lancet (London, England), 2011, Jul-09, Volume: 378, Issue:9786

Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Allylamine; Anticholesteremic Agents; Bariatric Surgery; Bile Acids and Salts; Cardiovascular System; Colesevelam Hydrochloride; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucokinase; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liver; Obesity; Peptides; Randomized Controlled Trials as Topic; Receptors, Dopamine D2; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Venoms

2011

Other Studies

1 other study(ies) available for allylamine and Obesity

Article	Year
Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 298, Issue:3 Topics: Allylamine; Animals; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Body Weight; Carrier Proteins; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Colesevelam Hydrochloride; Cyclic N-Oxides; Dietary Carbohydrates; Dietary Fats; Gene Expression; Glucagon-Like Peptide 1; Glucose Tolerance Test; Ileum; Insulin; Insulin Resistance; Liver; Male; Membrane Glycoproteins; Obesity; Organic Anion Transporters, Sodium-Dependent; Portal Vein; Rats; Rats, Inbred F344; Receptors, Cytoplasmic and Nuclear; Symporters; Triglycerides; Tropanes	2010

Article

Year

Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.

American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 298, Issue:3

Topics: Allylamine; Animals; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Body Weight; Carrier Proteins; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Colesevelam Hydrochloride; Cyclic N-Oxides; Dietary Carbohydrates; Dietary Fats; Gene Expression; Glucagon-Like Peptide 1; Glucose Tolerance Test; Ileum; Insulin; Insulin Resistance; Liver; Male; Membrane Glycoproteins; Obesity; Organic Anion Transporters, Sodium-Dependent; Portal Vein; Rats; Rats, Inbred F344; Receptors, Cytoplasmic and Nuclear; Symporters; Triglycerides; Tropanes

2010